Manufacturing News and Research

RSS

Manufacturing is the production of products across all industries, on a large-scale, using machinery.

Pfizer commences recruitment for Phase I clinical trial of SA3Ag vaccine

Inhibitex, Inc. today announced that its collaborator, Pfizer, Inc., has initiated patient recruitment for 408-patient, randomized, double-blind Phase I clinical trial to evaluate the safety, tolerability, and immunogenicity of three ascending dose levels of a 3-antigen Staphylococcus aureus (S. aureus) vaccine (SA3Ag) in healthy adults.

12 Jan 2010

QIAGEN N.V. announces acquisition of ESE GmbH for $19 million

QIAGEN N.V. today announced that it has acquired ESE GmbH, a privately held developer and manufacturer of UV and fluorescence optical measurement devices. ESE is based in Stockach, Germany. The transaction is valued at up to US$19 million in cash.

From QIAGEN Manchester Limited 12 Jan 2010

ViroPharma signs agreement with Sanquin Blood Supply Foundation to develop and commercialize Cinryze

ViroPharma Incorporated today announced that it has signed an agreement with Sanquin Blood Supply Foundation for rights to develop, file regulatory dossiers, and commercialize Cinryze(TM) (C1 esterase inhibitor [human]) for hereditary angioedema (HAE) as well as for potential new indications in certain European and rest of world (ROW) territories.

12 Jan 2010

Pharmaron Holdings acquires Bridge Laboratories China

Pharmaron Holdings Limited, today announced it completed the acquisition of Bridge Laboratories China. Bridge Laboratories China is the leading contract research organization (CRO) in China providing western standard GLP-compliant toxicology services to pharmaceutical and biotech companies from around the world. With this acquisition, Pharmaron becomes the first integrated CRO in China supporting clients with drug discovery and development processes in support of IND filings. This strategic acquisition strengthens Pharmaron's leading position in the fast-growing, highly dynamic pharmaceutical CRO industry.

12 Jan 2010

Research suggests ancient Egyptians may have used lead-based cosmetics to prevent eye infections

There's more to the eye makeup that gave Queen Nefertiti and other ancient Egyptian royals those stupendous gazes and legendary beauty than meets the eye. Scientists in France are reporting that the alluring eye makeup also may have been used to help prevent or treat eye disease by doubling as an infection-fighter.

12 Jan 2010

Antares Pharma, Population Council report positive Phase 2 results for novel NES/E2 contraceptive gel

Antares Pharma, Inc. and the Population Council today announced successful results from a dose-finding Phase 2 trial for a novel contraceptive gel containing the progestin Nestorone and estradiol (NES/E2) utilizing the Antares ATD (advanced transdermal delivery) gel system. Based on this successful data, the two parties continue to expect to partner with a worldwide or regional pharmaceutical company in order to commercialize this novel contraceptive gel.

12 Jan 2010

BioCryst Pharmaceuticals signs agreements with two additional partners

BioCryst Pharmaceuticals, Inc. today announced that it has signed agreements with two additional partners who will exclusively represent BioCryst and its anti-viral peramivir for influenza stockpiling opportunities for territories outside of the U.S. BioCryst's new partners are Merck Serono for Europe, Russia, Canada and Singapore and Hikma Pharmaceuticals PLC for the Middle East and North Africa (MENA) region, excluding Israel.

12 Jan 2010

Targacept signs collaboration and license agreement with AstraZeneca

Targacept, Inc., a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR Therapeutics™, today announced that its collaboration and license agreement with AstraZeneca for the global development and commercialization of TC-5214 for major depressive disorder (MDD) has become effective as a result of early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act.

11 Jan 2010

Tampa Bay Partnership releases new briefs on the economic and business growth in the Tampa Bay Region

SRI International Dedicates New Tampa Bay Research Facility SRI International, one of the world's leading independent research and technology development organizations, officially opened its new 40,000-square-foot research facility located at the Port of St. Petersburg.

11 Jan 2010

Biotage finalizes transfer of its manufacturing business from Charlottesville, Virginia

Biotage announced on 22 January 2009 that the company had decided to move the manufacturing of its products from its factory in Charlottesville, Virginia, to contract manufacturers and Biotage’s manufacturing plant in Cardiff, Wales. The transfer of this business has now successfully been finalized.

11 Jan 2010

Vertex Pharmaceuticals plans proof-of-concept clinical trials in RA and epilepsy

Vertex Pharmaceuticals Incorporated today provided an update on key 2010 business priorities in conjunction with the 28th Annual J.P. Morgan Healthcare Conference in San Francisco. The company also discussed recent progress in its lead development programs in hepatitis C virus (HCV) infection and cystic fibrosis (CF) and outlined proof-of-concept clinical trials planned in other serious diseases for 2010.

11 Jan 2010

Quidel to acquire Diagnostic Hybrids for $130M

Quidel Corporation, a leading provider of rapid point-of-care diagnostic tests, announced today the signing of a definitive agreement to acquire privately held Diagnostic Hybrids, Inc. for approximately $130 million in cash.

10 Jan 2010

SeraCare Life Sciences launches new products to aid discovery and development of drugs and diagnostics

SeraCare Life Sciences, Inc. announced today that the Company has added five new, differentiated products to its portfolio to meet the needs of SeraCare’s growing customer base in the life sciences industry.

9 Jan 2010

Acetylon Pharmaceuticals to utilise additional funding in multiple myeloma drug development

Acetylon Pharmaceuticals, Inc. announced today that it has closed on a $2 million investment from a new undisclosed private investor to bring its total financing to $9.25 million. This new investment will convert to stock in the next substantial round of preferred equity financing.

9 Jan 2010

NexMed updates corporate activities

NexMed, Inc., a specialty CRO and a developer of products based on the NexACT® technology, today provided an update on ongoing corporate activities and the status of the Company’s NASDAQ listing.

9 Jan 2010

FDA yet to review MannKind’s NDA for insulin therapy

MannKind Corporation announced that it was informed today by the Food and Drug Administration that the FDA will not be able to complete the review of MannKind’s new drug application (NDA) for its ultra rapid-acting insulin therapy by the action date of January 16, 2010.

9 Jan 2010

ChiroCode Institute and Avazzia jointly promote advanced technology devices

ChiroCode Institute and Avazzia will jointly promote advanced technology devices that help chiropractors and other caregivers manage their patients' chronic pain. The Avazzia BEST Pro Sport device combines microcurrent transcutaneous stimulation with somatic bio-feedback to provide improved results while making obsolete existing TENS devices.

9 Jan 2010

Savient Pharmaceuticals announces filing of KRYSTEXXA BLA resubmission on track

Savient Pharmaceuticals, Inc. provided an update on its activities directed toward the resubmission of its Biologics License Application (BLA) for KRYSTEXXA(TM) (pegloticase) as a treatment for chronic gout in patients refractory to conventional therapy and reaffirmed its belief that it continues to be on track for the filing of the BLA resubmission for KRYSTEXXA in the first quarter of 2010.

9 Jan 2010

Sybaritic to stop production and distribution of medical devices

Sybaritic Inc., a medical device maker, has agreed to stop producing and distributing its medical products used in laser surgery, dermatology, and spa treatments until it is in compliance with FDA quality standards.

8 Jan 2010

Synta Pharmaceuticals announces pricing of public offering of shares

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced the pricing of an underwritten public offering of 5,555,556 shares of its common stock at a price to the public of $4.50 per share for gross proceeds of approximately $25 million.

8 Jan 2010

Manufacturing News and Research

Further Reading

Pfizer commences recruitment for Phase I clinical trial of SA3Ag vaccine

QIAGEN N.V. announces acquisition of ESE GmbH for $19 million

ViroPharma signs agreement with Sanquin Blood Supply Foundation to develop and commercialize Cinryze

Pharmaron Holdings acquires Bridge Laboratories China

Research suggests ancient Egyptians may have used lead-based cosmetics to prevent eye infections

Antares Pharma, Population Council report positive Phase 2 results for novel NES/E2 contraceptive gel

BioCryst Pharmaceuticals signs agreements with two additional partners

Targacept signs collaboration and license agreement with AstraZeneca

Tampa Bay Partnership releases new briefs on the economic and business growth in the Tampa Bay Region

Biotage finalizes transfer of its manufacturing business from Charlottesville, Virginia

Vertex Pharmaceuticals plans proof-of-concept clinical trials in RA and epilepsy

Quidel to acquire Diagnostic Hybrids for $130M

SeraCare Life Sciences launches new products to aid discovery and development of drugs and diagnostics

Acetylon Pharmaceuticals to utilise additional funding in multiple myeloma drug development

NexMed updates corporate activities

FDA yet to review MannKind’s NDA for insulin therapy

ChiroCode Institute and Avazzia jointly promote advanced technology devices

Savient Pharmaceuticals announces filing of KRYSTEXXA BLA resubmission on track

Sybaritic to stop production and distribution of medical devices

Synta Pharmaceuticals announces pricing of public offering of shares

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest Life Science News